Supplementary Table 1. Ocular characteristics in different treatment of OTB

Characteristics	ATT		Without ATT
	Treatment group A	Treatment group B	(Treatment group C)
	N = 40, (%)	N = 21, (%)	N = 32, (%)
Bilateral	21 (52.5)	14 (66.7)	16 (50.0)
Only presenting with anterior uveitis**	10 (25.0)	3 (14.3)	18 (56.3)
BCVA category			
No-mild VI	24 (66.7)	13 (65.0)	23 (71.9)
Moderate VI	4 (11.1)	3 (15.0)	6 (18.8)
Severe VI	0 (0)	1 (5.0)	0 (0)
Blind	8 (22.2)	3 (15.0)	3 (9.4)
AC cells $\geq$ 2+	5 (14.3)	5 (27.8)	4 (12.5)
Granulomatous AC inflammation			
Posterior syneciae	6 (15.0)	3 (14.3)	9 (28.1)
Vitreous cells	17 (42.5)	11 (52.4)	9 (28.1)
Serpiginous-like choroiditis*	1 (2.5)	3 (14.3)	0 (0)
Tuberculoma	2 (5.0)	2 (9.5)	0 (0)
Other type of choroiditis*	4 (10.0)	7 (33.3)	3 (9.4)
Retinal lesions	3 (7.5)	4 (19.0)	3 (9.4)
Retinal vasculitis	8 (20.0)	8 (38.1)	4 (12.5)
Non-glaucomatous optic nerve involvement	6 (15.0)	4 (19.0)	4 (12.5)
Macular edema	12 (30.0)	3 (14.3)	8 (25.0)

Between groups comparison *p <0.05, ** p<0.01
AC = anterior chamber, ATT = anti-tubercular treatment, BCVA = best-corrected visual acuity, IMT = immunosuppressive drugs, VI = visual impairment.
Treatment groups: A (ATT ± local steroid without systemic CS/IMT), B (ATT ± local steroid with systemic steroid/IMT), and C (without ATT (local ± systemic CS)).

Supplementary Table 2. Proportion of relapse according to ATT treatment and anatomical site of uveitis at baseline presentation

ATT	Anatomical site of baseline uveitis	Total patients N = 75, %	Relapse, No. (%)	
			Yes	No
Yes – treatment group A and B (N =54)	Anterior uveitis	13/54 (24.1)	6/13 (46.2)	7/13 (53.8)
	Intermediate uveitis	4/54 (7.4)	3/4 (75.0)	1/4 (25.0)
	Posterior uveitis	16/54 (29.6)	2/16 (12.5)	14 (87.5)
	Panuveitis	20/54 (37.0)	7/20 (35.0)	13/20 (65.0)
	Episclero/sclerouveitis	1/54 (1.8)	0/1 (0)	1/1 (100)
No – treatment group C (N=21)	Anterior uveitis	15/21 (71.4)	4/15 (26.7)	11/15 (73.3)
	Intermediate uveitis	0/21 (0)	0	0
	Posterior uveitis	1/21 (4.8)	0/1 (0)	1/1 (100)
	Panuveitis	4/21 (19.0)	2/4 (50.0)	2/4 (50.0)
	Episclero/sclerouveitis	0/21 (0)	0	0
	Discrepant between right-left eyes	1/21 (4.8)	1/1 (100)	0/1 (0)

Row percentages are displayed in relapse yes and no columns
Treatment groups: A (ATT ± local steroid without systemic CS/IMT), B (ATT ± local steroid with systemic steroid/IMT), and C (without ATT (local ± systemic CS))

Supplementary Table 3. Details of baseline characteristics, 6-month inflammation status, the occurrence of the first uveitis relapse episode, and last follow-up condition of 25 patients with uveitis relapse

No	Age (years)	Sex	Anatomical site of initial uveitis	Initial QFT value (IU/ml)	Initial treatment group	6-month condition		Time-to-uveitis inactivity (month)	Time-to-uveitis relapse (month)	First episode of uveitis relapse				Last follow-up condition	
						Response to treatment	Still-in-use drugs			Still-in-use drugs at the first notification for uveitis relapse	Anatomical site of uveitis	New QFT value (IU/ml)	Duration of follow-up (month)	Uveitis activity	Still-in-use drugs
1	27	Female	Anterior	23.85	C	Good	No drugs	1	63	No drugs	Anterior	3.91	68	Inactive	Artificial tears 3x
2	51	Female	Anterior	10.44[a]	B	Poor	PF 3x/day and MTX 20mg/week	5.5	7	MTX 15 mg/week	Anterior	10.8	92	Inactive	No drugs
3	51	Male	Panuveitis	0.72	B	Poor	PF 2x/day and Mycophenolate sodium 3x720 mg	9	10	PF 2x/day and Mycophenolate sodium 3x720 mg	Panuveitis	0.01	113	Inactive	PF 1x
4	42	Female	Intermediate	10.43	A	Poor	PF 2x/day	8	27	No drugs	Intermediate	11.49	88	Inactive	Artificial tears
5	57	Female	Anterior	N/A	C	Poor	PF 2-4x/day	0.5	16	PF 2x/day	Anterior	14.9	106	Inactive	No drugs
6	64	Female	Anterior	3.8	C	Good	PF 1x/day	2	36	No drugs	Anterior	0.01	109	Inactive	PF 1x, latanoprost 1x (eft eye), nepafenac 1x right eye)
7	50	Female	Anterior	5.78	C	Poor	PF 4x/day	1	15	PF 1x/day	Anterior	7.72	15	Inactive	PF 1x
8	55	Male	Anterior	N/A	B	Good	PF 1-2x/day	5.5	2.8	PF 1-2x/day	Anterior	9.89	224	Inactive	No drugs
9	48	Female	Panuveitis	1.01 [b]	A	Good	No drugs	2	11	No drugs	Panuveitis	N/A	111	Inactive	No drugs
10	51	Female	Anterior	16.65	A	Good	No drugs	10.5	27	No drugs	Anterior	13.64	151	Inactive	Artificial tears
11	53	Female	Panuveitis	0.74	B	Poor	Oral prednisone 10mg/day and Mycophenolate sodium 3x360 mg	6	15	Tocilizumab 1x/week, Prednison 7.5mg/day, and Mycophenolate sodium 2x360 mg	Anterior	0.01	58	Inactive	Tocilizumab 1x/week, Oral prednison 5mg/daily, mycophenolate sodium 2x360mg
12	54	Male	Panuveitis	3.58	C	Good	Nepafenac 1x/day	2	9	No drugs	Anterior	N/A	17	Inactive	Dorzolamide/timolol 2x, latanoprost 1x, nepafenac 1x, MTX
13	66	Male	Intermediate	2.1	A	Good	Nepafenac 1x/day	1	42	Dexamethasone drop 1x/day	Anterior	N/A	51	Inactive	Oral acetazolamide 2x250mg, nepafenac 2x, tocilizumab 1x/2week
14	53	Female	Anterior	0.95	A	Good	No drugs	0.5	52	No drugs	Episclero/sclero-uveitis	0.12	111	Inactive	Tocilizumab 1x/2week
15	63	Female	Panuveitis	0.62	B	Poor	Oral prednisone 10mg/day and dexamethasone drop 1x/day	5	5	Oral prednisone 10 mg/day	Intermediate	0.07	65	Inactive	Dexamethasone drops 1x
16	49	Male	Posterior	5.85	B	Poor	Oral prednisone 15 mg/day and MTX 15 mg/week	20	6	Infliximab 1x/8week and MTX 7.5mg/week	Anterior	N/A	42	Inactive	Infliximab 1x/4week, MTX 7.5mg/week, nepafenac 1x, dorzolamide/timolol 1x, PF 1x
17	51	Female	Anterior	1.17	C	N/A	No drugs	0.5	20	No drugs	Anterior	0.01	75	Inactive	No drugs
18	60	Female	Panuveitis	9.45	B	Poor	MTX 22.5 mg/week	19	7	MTX	Posterior	N/A	37	Inactive	No MTX anymore and no drops
19	48	Female	Anterior	N/A	A	Good	FML 1x/day	5.5	12	FML 1-2x/day	Anterior	0.08	87	Active	PF 3x
20	54	Female	Posterior	N/A	B	Poor	MTX 15 mg/week	6	11	Dexamethasone drop 3x/day	Panuveitis	N/A	61	Active	-
21	63	Male	Panuveitis	1.22	C	Poor	Adalimumab 1x/2 week and PF 1x/day	6	27	PF 1x/day	Anterior	0.14	116	Inactive	PF 2x OS
22	38	Male	Intermediate	12.7	A	Good	PF 1x/day	4	11	PF 1x/day	Panuveitis	N/A	16	Active	PF 3x, Nepafenac 3x, timoptol 2x, oral acetazolamide 2x125mg
23	53	Female	Anterior	1.64	A	Good	No drugs	2	7	No drugs	Episclero/sclero-uveitis	0.01	125	Inactive	MTX 10 mg/week, timolol 2x, latanoprost1x, artificial tears, Dexa 3x (left eye)
24	22	Male	Panuveitis	15.58	B	Poor	Post-vitrectomy	8	27	No drugs	Panuveitis	12.44	159	Inactive	Adalimumab 1x/2week
25	52	Female	Panuveitis	15.81	A	Poor	PF 1x/day	8	5	No drugs	Anterior	T.SPOT (positive)	116	Inactive	MTX 7.5 mg/week, adalimumab 1x/week

[a]Presented with concurrent Poncet's disease for initial uveitis episode; [b]Presented with concurrent lymphadenitis TB for initial uveitis episode

ATT = anti-tubercular treatment, CS = corticosteroid, FML = fluorometholone, IMT = immunosuppressive drugs, MTX = methotrexate, PF = prednisone acetate 1% , QFT = QuantiFERON-TB Gold

Uveitis activity: The presence of AC cells >0.5+ and/or clinically active intraocular inflammation (i.e., choroiditis, retinitis, or vasculitis)

Treatment group A: ATT (± local steroids), for patients treated without oral CS/IMT during the ATT course; treatment group B: combined ATT and CS/IMT, for those received CS/IMT during the ATT course for the initial uveitis presentation; and treatment group C: without ATT, if no ATT was being given and the patient was only treated with local and/or systemic IMT.

Supplementary Table 4. Median time to uveitis relapse and annual relapse-free proportions with stratification for initial anti-tubercular treatment and SUN classification of OTB

Variable	Total N=75	Initial treatment group, No. (%)		*P*	Patient group, No. (%)		*p*
		With ATT (Treatment group A and B) N= 54	Without ATT (Treatment group C) N=21		Group 1 N=16	Group 2 N=59	
Duration of follow-up until censored event* (month, median Q1-Q3)	11.9 (4.7-27.5)	10.8 (4.7-28.6)	15.0 (4.0-31.4)	0.804[a]	10.1 (3.7-71.5)	12.4 (27.5)	0.969[a]
Median survival time (month, 95% CI)	42.3 (12.7-71.9)	42.3 (10.9-73.8)	36.0 (13.4-58.5)	0.842[b]	N/A	36.0 (18.8-53.2)	0.426[b]
5-year relapse-free percentage							
Year 1	81%	75%	94%		70%	84%	
Year 2	68%	68%	69%		70%	68%	
Year 3	53%	55%	46%		70%	48%	
Year 4	49%	50%	46%		70%	43%	
Year 5	45%	44%	46%		70%	38%	

* With relapse: time to the first relapse episode; without relapse: time to the last clinic visit (the last follow-up time)
[a] Mann-Whitney U-test; [b] Log rank (Mantel-Cox) test
CI = confidence interval, IQR = interquartile range, N/A = not available (could not be calculated).
Treatment groups: A (ATT ± local steroid without systemic CS/IMT), B (ATT ± local steroid with systemic steroid/IMT), and C (without ATT (local ± systemic CS)).

Supplementary Table 5. Comparison of relapse parameters according to patient group and response to initial treatment stratified by treatment group

Treatment groups		Patient groups			Response to initial treatment		
		Group 1 N = 16, (%)	Group 2 N = 59, (%)	Log-rank test *p*-value	Good responders N = 45, (%)	Poor responders N = 21, (%)	Log-rank test *p*-value
Group A: ATT ± local steroid without systemic CS/IMT	Total subjects	10 (62.5)	25 (42.4)		27 (60.0)	4 (19.0)	
	N relapse	1/10 (10.0)	8/25 (32.0)		7/27 (25.9)	2/4 (50.0)	
				0.176			0.548
	Relapse rate*	0.03	0.17		0.11	0.18	
Group B: ATT ± local steroid with systemic steroid/IMT	Total subjects	6 (37.5)	13 (22.0)		5 (11.1)	12 (57.1)	
	N relapse	3/6 (50.0)	6/13 (46.2)		1/5 (20.0)	8/12 (66.7)	
				0.831			0.405
	Relapse rate*	0.45	0.40		0.18	0.49	
Group C: Without ATT (local ± systemic CS)	Total subjects	0 (0)	21 (35.6)		13 (28.9)	5 (23.8)	
	N relapse	0/0 (0)	7/21 (33.3)		3/13 (23.1)	3/5 (60.0)	
				N/A			0.175
	Relapse rate*	N/A	0.19		0.12	0.30	
All patients	N relapse	4/16 (25.0)	21/59 (35.6)		11/45 (24.4)	13/21 (61.9)	
	Relapse rate*	0.10	0.21	0.426	0.12	0.35	0.016

* Relapse-rate per person-year
N/A = Not applicable
Patient groups: 1 (fulfilled the SUN classification criteria and/or had active systemic TB) and 2 (fulfilled COTS criteria but did not fulfil the SUN classification criteria for OTB)
Response to initial treatment: Good responders (met all of the following criteria at the first six months of treatment for initial uveitis episode: (1) absence of active inflammation in the retina, choroid, episclera, or sclera, with both eyes showing ≤ 0.5+ AC or vitreous cells; (2) oral prednisone or its equivalent reduced to less than 10 mg daily; (3) topical 1% prednisolone acetate (or equivalent) reduced to no more than two drops daily, (4) discontinuation of immunosuppressant therapy with the exception of prednisone use less than 10 mg daily) and poor responders (did not achieve the aforementioned criteria).

Supplementary Table 6. Comparison of clinical presentation and its management between initial uveitis and subsequent episodes of uveitis relapse

Variables	Initial uveitis	First uveitis relapse episode	Second uveitis relapse episode	Third uveitis relapse episode
Patient level				
N patient	75	25	13	7
Need IMT/biologic for treatment of presenting uveitis episode	10 (13.3%)	9 (36.0%)	5 (38.5%)	3 (42.9%)
Ocular level				
N eyes	137	41	20	8
AC cells[a]				
≥2+	17 (13.2%)	14 (34.1%)	2 (10.0%)	4 (50.0%)
<2+	112 (86.8%)	27 (65.9%)	18 (90.0%)	4 (50.0%)
Visual acuity (LogMAR; median, Q1-Q3)	0.22 (0.00-0.65)	0.17 (0.00-0.73)	0.20 (0.00-0.62)	0.30 (0.18-0.70)

a Data of AC cells at initial presentation is available/identifiable in 129 eyes
AC = anterior chamber, IMT = immunosuppressive drugs, IQR = interquartile range